Immunovia announces determined exercise price for warrants series TO 3

LUND, Sweden, March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in the warrants is 11 April 2025.

Immunovia carried out a rights issue of units during August – September 2024 (the "Rights Issue"). Each unit issued in the Rights Issue consisted of two (2) shares, two (2) warrants series TO 2 and one (1) warrant series TO 3. One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the Company. If all warrants are exercised, Immunovia will receive approximately SEK 14.9 million before issue costs.

The subscription price for the warrants was set at 70 percent of the volume-weighted average price for the Company's share on Nasdaq Stockholm during the period 14 – 27 March 2025, however not more than an amount corresponding to 150 percent of the subscription price per share in the Rights Issue (SEK 0.76 per share). 70 percent of the volume-weighted average price during the pricing period amounted to approximately SEK 0.24 per share, and thus the subscription price is set at SEK 0.24 per share.

Summary of instructions and important dates

Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at the latest on 15 April 2025. Warrants that have not been exercised on or before 15 April 2025 expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including 11 April 2025.

Detailed information and instructions for subscription

Exercise of nominee-registered warrants

Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 15 April 2025 as different nominees have different processing times.

Exercise of directly registered warrants

Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Vator Securities AB, no later than 15 April 2025.

The application form is available on the Company's and Vator Securities AB's respective websites (www.immunovia.com and www.vatorsecurities.se). Please note that payment for the new shares must be received by Vator Securities no later than 15 April 2025 in accordance with the instructions on the application form.

Trading in TO 3

Holders who do not wish to exercise their warrants may sell them on Nasdaq Stockholm. The warrants are traded up to and including 11 April 2025 under the short name IMMNOV TO 3 and with ISIN code SE0022600102. Warrants that are not exercised on 15 April 2025 at the latest will expire without value.

Outcome and delivery of new ordinary shares

The outcome of the exercise of warrants will be published via a press release on or around 17 April 2025. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Immunovia.

Change in share capital and number of shares 

Upon full exercise of all 62,211,989 warrants series TO 3, the share capital will increase by a maximum of SEK 1,866,359.67 to SEK 9,723,625.56 through the issuance of a maximum of 62,211,989 new shares, resulting in that the total number of outstanding shares in the Company will increase from 261,908,863 to 324,120,852. Upon full exercise of all warrants series TO 3, the dilution amounts to approximately 19.2 percent.

Complete terms and conditions for the warrants

Complete terms and conditions for the warrants are available on the Company's website, www.immunovia.com. 

Advisers

Vator Securities AB acts as financial adviser to Immunovia in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Immunovia in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact
Jeff Borcherding, CEO
[email protected]

The information was submitted for publication, through the agency of the contact persons set out above, at 20:40 CET on 27 March 2025.

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Immunovia. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Immunovia has only been made through the prospectus published by Immunovia on 12 August 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.immunovia.com. 

Since Immunovia is considered to carry out protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). The Company will, no later than in connection with the commencement of the exercise period for the warrants, publish more information about this on the Company's website, www.immunovia.com. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-announces-determined-exercise-price-for-warrants-series-to-3,c4125701

The following files are available for download:

SOURCE Immunovia AB